Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medlive Technology CoHKSE:02192 +0.90%90 EV-to-FCF is 11.77 as of Aug. 03, 2026, which is 53% below its 10-year median of 25.07. GuruFocus rates HKSE:02192 with a GF Score™ of 90/100 and a GF Value™ of HK$14.95 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 405 Healthcare Providers & Services companies, Medlive Technology Co ranks better than 65.43% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Medlive Technology Co's Enterprise Value is HK$1,574.5 Mil.
Medlive Technology Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was HK$133.8 Mil. Therefore, Medlive Technology Co's EV-to-FCF for today is 11.77.
The historical rank and industry rank for Medlive Technology Co's EV-to-FCF or its related term are showing as below:
HKSE:02192'
s EV-to-FCF Range Over the Past 10 Years
Min: -12.93 Med: 25.07 Max: 242.02
Current: 11.77
During the past 8 years, the highest EV-to-FCF of Medlive Technology Co was 242.02. The lowest was -12.93. And the median was 25.07.
HKSE:02192's EV-to-FCF is ranked better than 65.43% of 405
companies
in the Healthcare Providers & Services industry
Industry Median: 17.83
vs HKSE:02192: 11.77
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Medlive Technology Co (HKSE:02192) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Medlive Technology Co's PE Ratio (TTM) for today is calculated as:
Medlive Technology Co's share price for today is HK$7.87.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Medlive Technology Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was HK$0.499.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:02192 vs VEEV, BTSG, HQY: EV-to-FCF Comparison
For the Health Information Services subindustry, Medlive Technology Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medlive Technology Co EV-to-FCF vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Medlive Technology Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Medlive Technology Co's EV-to-FCF falls into.
Medlive Technology Co's current Enterprise Value is HK$1,574.5 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Medlive Technology Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was HK$133.8 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medlive Technology Co (HKSE:02192) has a EV-to-FCF of 11.77 as of Aug. 03, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Medlive Technology Co and its competitors. This is 53% below median its historical median of 25.07. According to the industry distribution chart, Medlive Technology Co ranks #140 out of 405 companies in the Healthcare Providers & Services industry, placing it in the top 34.6%.
Is Medlive Technology Co's EV-to-FCF too high?
Medlive Technology Co's current EV-to-FCF of 11.77 is 53% below median its 10-year median of 25.07. The Healthcare Providers & Services industry median EV-to-FCF is 17.83. Medlive Technology Co's value of 11.77 is 34% below this industry median. Based on the distribution chart, Medlive Technology Co ranks #140 out of 405 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Medlive Technology Co has a GF Score™ of 90/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medlive Technology Co's EV-to-FCF compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Medlive Technology Co ranks #140 out of 405 companies for EV-to-FCF. This puts Medlive Technology Co in the upper half of its industry. The industry median EV-to-FCF is 17.83. Medlive Technology Co's value of 11.77 is 34% below this benchmark. While the company's 10-year median is 25.07 vs. the industry median of 17.83, Medlive Technology Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Healthcare Providers & Services company?
The median EV-to-FCF among Healthcare Providers & Services companies is 17.83, based on 405 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medlive Technology Co's current EV-to-FCF of 11.77 is 34% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Medlive Technology Co and its competitors. For the Healthcare Providers & Services industry, the median EV-to-FCF is 17.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medlive Technology Co's current EV-to-FCF is 11.77, which is 53% below median its own 10-year median of 25.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medlive Technology Co stock overvalued right now?
Based on GuruFocus' analysis, Medlive Technology Co (HKSE:02192) is currently considered Significantly Undervalued. The stock's GF Value™ is HK$14.95, compared to a current price of HK$7.87 — trading 47.4% below its estimated fair value. The current EV-to-FCF is 11.77, which is 53% below median its 10-year median of 25.07 and 34% below the Healthcare Providers & Services industry median of 17.83. Medlive Technology Co's overall GF Score™ is 90/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Medlive Technology Co (HKSE:02192), the current EV-to-FCF is 11.77 as of Aug. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medlive Technology Co (HKSE:02192) Overvalued in 2026?
Based on GuruFocus' analysis, Medlive Technology Co stock appears to be undervalued.
The current stock price of HK$7.87 is trading 47.4% below its estimated GF Value™ of HK$14.95.
GuruFocus considers Medlive Technology Co to be Significantly Undervalued.
Key valuation signals for HKSE:02192:
EV-to-FCF: 11.77 (53% below median its 10-year median of 25.07)
GF Value™: HK$14.95 vs. price of HK$7.87 (47.4% below fair value)
Industry Position: 34% below the Healthcare Providers & Services median (#140 of 405)
No single metric tells the full story. See the HKSE:02192 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medlive Technology Co Ltd is a digital healthcare marketing company that produces customized content for pharmaceutical and medical device firms. The company developed into a professional provider of medical information services and precision digital marketing services. Its platform also provides medical content consisting of third-party research, informal discussions, and medical news articles. The company also operates a minor internet hospital and a SaaS solution that helps with medical conferences and clinical research.
90GF Score
Get the complete analysis for HKSE:02192
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02192 has been successfully added to your 
